Industry Briefing
November 7, 2026
Hepatitis B and C Took 1.34 Million Lives in a Single Year, and Those Deaths Were Largely Preventable
Editorial Department, American Chamber of Health

The World Health Organization counts 287 million people living with chronic hepatitis B or hepatitis C. In the most recent year assessed, the two infections took 1.34 million lives. A vaccine prevents hepatitis B and a short course of medicine cures hepatitis C, yet those tools are reaching almost none of the people who need them, and the world is off track to eliminate viral hepatitis as a public health threat by 2030.
Hepatitis B and hepatitis C are quiet infections. Both are viruses that attack the liver. Most people who carry them feel nothing for years, sometimes for decades, while the infection slowly scars the liver. That scarring, called cirrhosis, and liver cancer are the main causes of death in people with chronic hepatitis. By the time symptoms appear, the damage is often advanced and the options are few.
Chronic means the infection stays in the body rather than clearing. Of the 287 million people living with chronic infection, an estimated 240 million have hepatitis B and 47 million have hepatitis C. Around 1.1 million of the deaths in the year assessed were caused by hepatitis B, and around 240,000 by hepatitis C.
Elimination, as the World Health Organization uses the word, does not mean the viruses vanish. It means new infections and deaths fall far enough that hepatitis no longer stands among the major causes of death. Member states adopted that goal with a target year of 2030. The current report measures how far the world has come since 2015, and how much ground is left.
"Around the world, countries are showing that eliminating hepatitis is not a pipedream, it's possible with sustained political commitment, backed by reliable domestic financing," said Dr Tedros Adhanom Ghebreyesus, WHO Director General. "At the same time, this report shows that progress is too slow and uneven. Many people remain undiagnosed and untreated due to stigma, weak health systems and inequitable access to care." The tools to eliminate hepatitis as a public health threat already exist, he said. What is missing is speed: prevention, diagnosis and treatment have to reach far more people, far faster, if the world is to meet the 2030 targets.
The Gains Are Real
The progress since 2015 is genuine, and the numbers show it.
New hepatitis B infections have fallen by 32 percent. Deaths from hepatitis C have fallen by 12 percent. Among children under five, the share living with chronic hepatitis B has fallen to 0.6 percent, and 85 countries have reached the 2030 target of 0.1 percent or lower in young children. That last figure is the hepatitis B vaccine working across a generation: children protected at birth do not become the chronic cases of the next decade.
The World Health Organization also points to countries, among them Egypt, Georgia, Rwanda and the United Kingdom, where progress demonstrates that elimination is achievable with sustained commitment and investment. These are different health systems on different continents. What they share is that hepatitis was treated as a program to run, not a problem to describe.
Where the Response Falls Short
Set against those gains, the treatment numbers are stark.
Of the 240 million people living with chronic hepatitis B, fewer than 5 percent were receiving treatment, even though around half of them meet the World Health Organization's own treatment guidelines. For hepatitis C, only 20 percent of people have been treated since a curative treatment became available, and 11 million people who have been diagnosed with hepatitis C were still not on treatment in the year assessed. These are not people the system failed to find. They were found, and then left waiting.
The death figures tell the same story. Deaths from hepatitis B, around 1.1 million in the year assessed, are 17 percent higher than they were in 2015. Deaths from hepatitis C have fallen, but new hepatitis C infections have fallen by only 8 percent, far from the 2030 target of an 80 percent reduction.
Prevention is thinnest where the burden is heaviest. The World Health Organization's African Region accounted for 68 percent of new hepatitis B infections, yet only 17 percent of newborns there received the hepatitis B vaccine dose given at birth. People who inject drugs accounted for 44 percent of new hepatitis C infections, while harm reduction services reach only a fraction of what the targets call for: an average of 35 needles and syringes distributed per person each year, against a 2030 target of 300.
The Tools Are Not the Problem
It is worth pausing on what already exists, because it changes what this story is about.
The hepatitis B vaccine protects more than 95 percent of vaccinated people against both acute and chronic infection. Long term antiviral treatment for hepatitis B can manage the chronic infection effectively and prevent severe liver disease. Treatment for hepatitis C, a course of medicine lasting 8 to 12 weeks, can cure more than 95 percent of infections.
A prevention tool, a management tool and a cure. The distance between the world as it is and the 2030 goal is not a research problem waiting on a breakthrough. It is a delivery problem: testing that does not happen, results that are not followed by treatment, vaccine doses that do not reach newborns in time.
What This Means for the American Healthcare Ecosystem
This is not only a story about health systems far from home. The United States is one of the ten countries that together account for 58 percent of hepatitis C deaths worldwide.
The American pattern is the global pattern in local form. Infection that stays silent for years. Testing that is offered late or not at all. A diagnosis that arrives only when the liver is already damaged, or a diagnosis that arrives in time and is not followed by treatment. A cure that exists, in a system where the patient and the cure never quite meet.
The work that closes a gap like this sits mostly in ordinary places. In primary care, where a hepatitis test can be offered to adults who have never had one. In laboratories and clinics that follow through on results instead of filing them. In vaccination given on schedule, starting at birth. In treatment started promptly for the people already diagnosed, who are the easiest group in this entire report to help, because the system already knows who they are.
For the American Chamber of Health, which exists to connect providers, health systems, public health leaders and healthcare innovators, this report underlines a familiar lesson. Conditions are rarely beaten by tools alone. They are beaten when testing, counseling, treatment and follow up are organized as one connected service, and when someone is accountable for the patient moving from one step to the next. From Houston, Texas and Cary, North Carolina, ACH sees the same thing in community after community: the capacity exists somewhere in the system, and what the patient actually experiences depends on whether the parts work together.
What Would Move the Numbers
The World Health Organization's priorities are plain, and they begin with finding people.
"The data shows that progress is possible but also reveals where we are falling short. Every missed diagnosis and untreated infection due to chronic viral hepatitis represents a preventable death," said Dr Tereza Kasaeva, Director, WHO Department for HIV, TB, Hepatitis and Sexually Transmitted Infections. "Countries must move faster to integrate hepatitis services for people living with hepatitis B and C into primary care, and to reach the communities most affected."
Three things would change the trajectory.
Testing first. Most people living with hepatitis B or C do not know it. Wider testing, built into primary care rather than held in specialist corners, is how the undiagnosed majority becomes a treatable caseload.
Treatment access second. The fastest gains are among people already diagnosed, including the 11 million with hepatitis C still waiting for a cure that takes weeks. Scaling up hepatitis B treatment matters most where deaths are concentrated, in the African and Western Pacific regions, and hepatitis C treatment in the Eastern Mediterranean Region.
Vaccination third. The birth dose of hepatitis B vaccine, given in the first day of life, and preventive treatment for mothers who carry the virus, are what stop the next generation of chronic infection. Coverage of that single dose is the weakest where new infections are most common.
Alongside all three, injection safety in clinics and in the community, and real harm reduction services for people who inject drugs, address the route by which hepatitis C continues to spread.
The World Health Organization's own conclusion is direct: without a rapid scale up of testing and treatment, the target of a 65 percent reduction in hepatitis deaths by 2030, measured against 2015, will not be achieved.
The measure of this report is not whether the world has the tools. It does. The measure is whether health systems test the people who do not know they are infected, treat the people already diagnosed and waiting, and vaccinate every child in time.
Sources and Editorial References
1. World Health Organization | April 28, 2026
Efforts to eliminate hepatitis delivers gains but more action needed to meet 2030 targets
News release presenting the Global Hepatitis Report 2026, including the global burden figures, the treatment and vaccination gaps, the tools available, and the statements of Dr Tedros Adhanom Ghebreyesus and Dr Tereza Kasaeva quoted in this briefing.
https://www.who.int/news/item/28-04-2026-efforts-to-eliminate-hepatitis-delivers-gains-but-more-action-needed-to-meet-2030-targets
2. World Health Organization | Global Hepatitis Report 2026
Global hepatitis report 2026
Report page and information sheet summarizing the report's key findings: progress against the 2030 impact and service coverage targets, the 2024 burden estimates, treatment coverage, birth dose vaccination coverage, and the priorities for global and regional action.
https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis/reports/global-hepatitis-report-2026
Editorial Disclosure
This article is an independent industry briefing prepared by the American Chamber of Health Editorial Department. It is drawn entirely from the World Health Organization sources identified above.
All figures in this briefing are World Health Organization estimates, principally for the year 2024, the most recent year assessed in the report, with trends measured from 2015. They are modeled estimates built from country reporting, not counted cases, and they are presented in this briefing as estimates. The American Chamber of Health has not independently verified the figures or conducted its own epidemiological assessment.
Statements about what the evidence shows, including the assessment that elimination by 2030 is off track, are the World Health Organization's findings as published. The analysis of what the findings mean for the American healthcare ecosystem reflects the American Chamber of Health's editorial perspective.
This briefing does not constitute medical advice. Anyone concerned about hepatitis should speak with their own clinician about testing and vaccination.
